Reply to Harper
TO THE EDITOR-We are thankful for the interest in our article [1] by Harper and take this opportunity to clarify points that may have caused confusion.
Our follow-up study is a continuation of our original randomized controlled trial of alternative dosing schedules for quadrivalent human papillomavirus (HPV) vaccine among adolescent girls in Vietnam [2] and includes the same population. The original trial end point was immunogenicity 1 month after dose 3 [2] and resulted in type-specific results for noninferiority between the standard 0-, 2-, and 6-month dosing schedule and 3 alternative dosing schedules of 0, 3, and 9 months; 0, 6, and 12 months; and 0, 12, and 24 months [2] . Because other studies have demonstrated a waning immune response (measured in terms of geometric mean titers [GMTs]) over time among recipients of HPV vaccine [3] [4] [5] , we studied whether the same would be true for adolescents vaccinated using alternative dosing schedules. Therefore, we re-enrolled most of the original participants for collection of a follow-up blood specimen 29-32 months after their last dose of HPV vaccine. Because of the staggered start of the original trial, 66 girls vaccinated according to the standard 0-, 2-, and 6-month schedule were not eligible to be recruited for the follow-up study, because the time between their third dose and the start of our follow-up study was 36 months, which exceeded our planned immune response measurement 32 months after dose 3 [1] .
All participants in the original trial and, thus, all girls included in our followup study received all 3 doses of quadrivalent HPV vaccine according to their designated schedules. There were no additional doses of HPV vaccine given during our follow-up study; only a blood sample was taken to measure antibody response 29-32 months after dose 3. Because the timing of the alternative dosing schedules varied (as per the original trial design) [2] , the length of follow-up between receipt of the first dose and measurement of the immune response 1 month after dose 3 varied by schedule, as noted by Harper. As such, the time of measurement of the immune response before dose 3 also varied. We provided Figure 1 to illustrate the vaccination schedule, timing for measuring antibody responses, and length of time between each measurement for all dosing schedules [1] .
For all vaccine schedules, immune responses were significantly higher 1 month after the administration of the third dose, compared with those measured before dose 3 (ie, after 2 doses of HPV vaccine had been administered) [1, 2] . The magnitude of the boosting measured 1 month after dose 3 varied by schedule, with a larger boost observed for the standard 0-, 2-, and 6-month schedule ( Figure 3 [1] ). However, over time, and most likely because of the kinetics of waning antibody levels that has been demonstrated in other immunogenicity studies of quadrivalent HPV vaccine [3, 4] , the antibody concentrations 29-32 months after the third dose of HPV vaccine were similar, regardless of the original dosing schedule, and were noninferior to those associated with the standard 0-, 2-, and 6-month schedule (Table 1 [ 1] ). Although our results 1 month after dose 3 differed from those in the study by Zimmerman et al [6] , the long-term finding is that our alternative (extended) schedules are noninferior to those of the standard schedule. We assert that antibody concentrations measured 1 month after the third dose may be less clinically relevant than the longterm robustness of the response.
Even though our original trial and follow-up study were not designed to compare 2 versus 3 doses, we had an opportunity to investigate immune responses for all schedules after 2 doses because we obtained a blood specimen just before administering the third dose (Figure 1 [1] ). This analysis was exploratory, as subjects were not randomly assigned to a 2-dose schedule. For all schedules, by 32 months after dose 3, antibody titers waned to the level observed before dose 3 (ie, after the second dose) [1] . Intriguingly, for the 3 doses delivered on the alternative annual schedule of 0, 12, and 24 months, the immune response 12 months after dose 2 (at month 24) was similar to the immune response 32 months after dose 3 [1] . Additionally, the GMTs before dose 3 for this group (1572; 95% confidence interval [CI], 1366-1810) [1] were similar to those reported by Dobson et al for the 0-and 6-month 2-dose schedule, also measured 12 months after dose 2 (at month 18; 1579 [95% CI, 1322-1885]) [4] . This suggests that the antibody kinetics for 2 doses delivered at 0 and 6 months may not differ from those delivered at 0 and 12 months, but a properly conducted randomized controlled trial comparing these 2 schedules and the standard 0-, 2-, and 6-month 3-dose schedule, with long-term follow-up, will be necessary to provide a conclusive answer.
Although Harper has been an advocate for bivalent HPV vaccine [7] , the dramatic decline in genital warts in Australia and Denmark [8, 9] and the mounting evidence that flexible schedules for quadrivalent HPV vaccine are noninferior suggest that there is still a role for quadrivalent HPV vaccine in public health programs.
In conclusion, we found that delivery of 3 doses of quadrivalent HPV vaccine on alternative dosing schedules, including an annual schedule of 0, 12, and 24 months, did not result in inferior immune responses after >2.5 years of follow-up after the third dose. This new evidence for dosing flexibility could be helpful for settings where delivering 3 doses of HPV vaccine on a precise 0-, 2-, and 6-month schedule is challenging.
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